Published in Front Oncol on February 20, 2015
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia. Front Oncol (2016) 0.80
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin (2016) 0.77
Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b. J Exp Clin Cancer Res (2016) 0.76
Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms. Haematologica (2016) 0.75
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
MicroRNA expression and function in cancer. Trends Mol Med (2006) 7.02
Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell (1990) 6.12
Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A (2009) 5.30
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ (2009) 3.94
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev (1993) 3.62
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
Molecular cloning of cDNAs encoding two isoforms of the catalytic subunit of protein phosphatase 2A. Biochemistry (1987) 3.31
Alterations of the PPP2R1B gene in human lung and colon cancer. Science (1998) 3.14
PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci (2008) 3.04
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 2.86
Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol Cell Biol (1991) 2.80
MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology (2009) 2.57
MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene (2006) 2.47
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell (2013) 2.27
Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia (2009) 2.24
MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A (2008) 2.24
The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol (2010) 2.20
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry (1990) 2.03
Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol (2013) 2.03
Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci U S A (2002) 2.01
Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol (2006) 2.00
Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem (1995) 1.96
Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma (2009) 1.88
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene (2002) 1.85
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem (1994) 1.79
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood (2009) 1.76
MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood (2012) 1.75
The role of miRNAs in regulating gene expression networks. J Mol Biol (2013) 1.74
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J (2000) 1.63
MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res (2010) 1.61
Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res (2011) 1.59
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia (2011) 1.59
Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol (2008) 1.53
Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem (2004) 1.51
MiR-200, a new star miRNA in human cancer. Cancer Lett (2013) 1.50
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia (2009) 1.38
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev (2008) 1.37
MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ (2011) 1.37
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest (2013) 1.35
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol (2007) 1.34
MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One (2011) 1.33
MicroRNA function in myeloid biology. Blood (2011) 1.30
MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett (2014) 1.26
MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis (2010) 1.26
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood (2014) 1.19
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer (2010) 1.18
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest (2014) 1.17
MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene (2012) 1.17
Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IκB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology (2013) 1.16
A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev (2008) 1.14
Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett (2009) 1.10
miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn (2013) 1.08
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal (2013) 1.07
Cross talk between microRNA and coding cancer genes. Cancer J (2012) 1.06
MicroRNAs as Haematopoiesis Regulators. Adv Hematol (2013) 1.03
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer (2006) 1.03
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia (2011) 1.03
MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med (2012) 1.01
The structure of protein phosphatase 2A is as highly conserved as that of protein phosphatase 1. FEBS Lett (1990) 1.00
Identification of structural elements involved in the interaction of simian virus 40 small tumor antigen with protein phosphatase 2A. J Biol Chem (1998) 1.00
The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med (2012) 1.00
Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One (2012) 1.00
Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res (2010) 0.99
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem (2012) 0.97
Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia (2012) 0.96
Selective inhibition of IFNG-induced autophagy by Mir155- and Mir31-responsive WNT5A and SHH signaling. Autophagy (2013) 0.96
MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep (2009) 0.95
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia (2013) 0.95
Signaling from polyomavirus middle T and small T defines different roles for protein phosphatase 2A. Mol Cell Biol (1998) 0.94
PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem (2008) 0.93
miR-200c and GATA binding protein 4 regulate human embryonic stem cell renewal and differentiation. Stem Cell Res (2013) 0.92
High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol Cell Biochem (2011) 0.92
Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene (2012) 0.91
Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem (2013) 0.91
Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell (2013) 0.90
Developmental changes in hematopoietic stem cell properties. Exp Mol Med (2013) 0.89
Potential therapeutic applications of miRNA-based technology in hematological malignancies. Curr Pharm Des (2008) 0.89
Optimal suppression of protein phosphatase 2A activity is critical for maintenance of human embryonic stem cell self-renewal. Stem Cells (2010) 0.87
B56γ tumor-associated mutations provide new mechanisms for B56γ-PP2A tumor suppressor activity. Mol Cancer Res (2013) 0.85
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol (2013) 0.85
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. J Cell Physiol (2009) 0.83
Editorial: The Emerging Role for PP2A in Hematologic Malignancies. Front Oncol (2016) 0.75